Pharmaceutical R&D returns in 2026: How innovation Is measured and how it's reshaping hiring

In our experience, the hiring leaders who understand this distinction are running meaningfully different talent strategies from those who do not. ROI in pharmaceutical R&D is no longer just a finance team metric; it is a direct read on which therapy areas a company should be hiring into, which mechanisms of action need scientific firepower behind them, and where commercialisation talent will determine whether a strong asset becomes a strong launch. From what we see across hiring processes, the link between innovation investment and hiring strategy has tightened considerably in 2026.

This post does two things. First, it explains how R&D return is measured in 2026 and why the methodology matters for talent planning. Second, it sets out six strategic moves for hiring leaders responding to those numbers, with European salary benchmarks for the commercialisation roles in shortest supply right now.

The dominant industry metric is the projected internal rate of return on late-stage pipeline assets, calculated annually by Deloitte across the top 20 biopharma companies. The methodology models the capital outlay required to bring an asset through development against projected cash inflows from forecast peak sales, adjusted for the probability of technical and regulatory success and cycle time. It serves as a proxy measure for the industry's ability to balance R&D investment with the returns it actually generates.

The 2025 figures are more nuanced than the headline 7.0% suggests. Average forecast peak sales per asset across the cohort are now around €435m, but excluding GLP-1 therapies, that figure falls to roughly €315m, and IRR drops to 2.9%. Thirteen of the twenty companies tracked saw IRR growth, but only three exceeded a 5% increase. The cost of developing a new drug has continued to climb, reaching an average of €1.91bn in 2024, and Phase III clinical trial cycle times have lengthened by 12%, partly because competition for trial sites and eligible patients has intensified.

The most important pattern in the 2025 data is the link between novel mechanisms of action and IRR. Drugs with genuinely novel MoAs make up just 23.5% of the late-stage pipeline but are projected to generate 37.3% of forecast revenue. This is the clearest available signal for hiring leaders: companies that under-invest in novel-MoA programmes, and in the scientific talent required to develop them, are choosing the lower-return half of the pipeline by default. The ROI conversation has also widened beyond IRR alone; most major pharma companies now actively track value at risk from patent cliff exposure, AI-driven cost displacement, and time-to-market compression driven by IRA Medicare price negotiation in the US and the new EU Joint Clinical Assessment in Europe. Each of these has direct hiring implications.

Reading the numbers is one thing. Translating them into hiring decisions is another. The six moves below are the ones we are seeing pay off across European biopharma in 2026, drawn from the briefs that are being filled and the ones that are quietly stalling.

1. Build novel-MoA scientific depth before chasing the GLP-1 wave

The therapeutic concentration story of 2025 is impossible to ignore. Obesity, endocrine and metabolic disease have expanded rapidly behind GLP-1 and GIP success, drawing senior medical, clinical and commercial talent away from other therapeutic areas. Oncology remains the highest-revenue space and the most crowded, but the talent gravity has shifted noticeably. The longer-term return story, however, sits with novel mechanisms23.5% of the pipeline, 37.3% of projected value.

What to do now. Prioritise principal scientists and translational leaders with deep biology and mechanism-level fluency, not generalist drug developers. For biologics and advanced therapies, prioritise CMC and process science exposure within the candidate profile, since the manufacturing bottleneck on novel modalities is now a regular cause of launch slippage. Where senior scientific candidates are difficult to attract on base salary alone, lead with equity participation and milestone-linked compensation, novel-MoA work needs candidates who are comfortable with failure rates, and they are compensated accordingly.

The risk if you don't. A pipeline weighted toward fast-follower assets in crowded indications will continue to dilute IRR, and the scientific talent capable of moving novel programmes will go to the companies that have learned how to recruit them. We consistently see clients struggle to find this combination at the principal-scientist level. Waiting until the asset is in late preclinical means waiting too long.

2. Treat the EU Joint Clinical Assessment as a hiring driver, not a regulatory one

The EU Health Technology Assessment Regulation came into force on 12 January 2025, introducing a mandatory Joint Clinical Assessment (JCA) for new cancer medicines and advanced therapy medicinal products. Orphan medicines follow in 2028 and all other medicines in 2030. The JCA gives manufacturers around 100 days from receipt of the consolidated PICO scope to dossier submission, runs in parallel with the EMA review, and demands a substantially broader evidence base than any single national HTA. NICE in the UK, G-BA in Germany and HAS in France each remain critical at the national level, but the JCA is the new structural constraint sitting above them.

What to do now. If you have an oncology or ATMP asset within 24 months of approval, your HEOR, market access and RWE teams should already be hired and active. The compressed 100-day window does not accommodate sequential hiring. Build the team around four roles: a market access strategist who has run an EU-level submission, an HEOR manager who can model multi-country value across divergent payer systems, an RWE lead who can structure pre-launch evidence generation against the broader PICO scope, and a payer engagement specialist with credibility at G-BA, HAS and NICE. For rare disease and cell and gene therapy products, this team should be in place 24 months before approval, not twelve.

The risk if you don't. A clinically strong asset that fails the JCA gateway loses commercial momentum across 27 markets simultaneously. We are already seeing companies arrive at the JCA window understaffed and try to close the gap with consultants, which can patch the dossier, but cannot rebuild the multi-year evidence strategy the dossier should have been resting on.

3. Hire BD&L and integration leaders for the earlier-stage M&A pivot

With patent cliffs threatening major revenue streams, Merck's Keytruda, Bristol Myers Squibb's Eliquis, and a long list of other biopharma is increasingly buying smaller, earlier-stage assets rather than late-stage megadeals. Bayer's multi-year restructuring is targeting €2bn in annual savings by 2026, Takeda's transformation programme is targeting around €1.1bn, and several large pharma have explicitly redirected the freed capital toward bolt-on acquisitions and pipeline reinforcement.

What to do now. Strengthen the business development and licensing team with people who can value early-stage assets, not just price late-stage ones. Pair them with integration leaders who can absorb scientific teams without dismantling them. The worst outcome of an early-stage acquisition is losing the founding scientists in the first twelve months. Add translational scientists who can move acquired assets into the parent company's development engine. These three role types are the ones we are seeing in the highest demand against the thinnest available talent pool.

The risk if you don't. Deals get done, value gets paid, and the acquired science walks out the door inside a year. The hidden cost of poor integration is not the deal itself; it is the next deal the seller community does not bring to you.

4. Reframe AI investment as a commercial team redesign

Commercial AI spend in 2026 is increasingly funded from reductions in traditional SG&A rather than incremental budget. The composition of commercial teams is shifting to fewer field-based generalists, more digital engagement specialists, MLOps engineers, and AI-aware brand leaders. Pharma's enterprise AI implementation rate remains low, with only around 11% of organisations achieving enterprise-wide deployment. The gap is closing through hiring, not just through technology procurement.

What to do now. Audit your commercial headcount plan against the SG&A line. If the AI investment is funded but the corresponding role redesign has not happened, you are paying for both the legacy team and the new capability. Hire MLOps engineers and data engineers with regulated-environment experience, pharma data is not technology-sector data, and the candidates who understand the compliance overhead are scarce. For medical and commercial leaders, prioritise candidates who have actually run omnichannel engagement programmes in regulated markets, not those who have only managed traditional field teams.

The risk if you don't. The cost shows up twice: in the SG&A, you have not actually reduced, and in the commercial outcomes the AI investment was supposed to deliver. From what we see across hiring processes, this is one of the most common patterns of stalled AI ROI in 2026.

5. Move medical affairs, MSLs, and RWE upstream into pre-launch

Medical affairs has moved from a support function to a strategic pillar of launch. KOL engagement, scientific exchange and medical strategy now begin two or more years before approval, and the strongest MSL teams combine clinical credibility with digital fluency for omnichannel engagement. Real-world evidence generation now begins in pre-launch as well, both to support payer negotiations and to demonstrate value to providers operating in increasingly horizontally integrated health systems. Patient identification, particularly in rare diseases, oncology and advanced therapies, has shifted from a marketing function to a clinical-commercial bridge.

What to do now. Build the medical affairs leadership team, including TA leads and senior MSLs, eighteen to twenty-four months before approval, not after. Hire RWE and medical evidence managers in parallel; the candidates who can navigate EHR data, registries and patient-reported outcomes inside a regulated, HEOR-aware framework are genuinely scarce, and once they have committed to a competitor's launch, they are difficult to dislodge. For rare disease and ATMP assets, add a patient services and patient identification specialist with both clinical and commercial credibility. The teams that get this right capture meaningful share at launch.

The risk if you don't. Eligible patients go undiagnosed for months, KOL relationships are built in haste post-approval, and the payer conversation begins without the evidence it needed. A Phase III asset that succeeds technically can still fail commercially because the medical and evidence layer was assembled six months too late.

6. Make supply chain and CMC readiness a launch-stage hire, not an operations afterthought

Supply chain readiness has become unexpectedly central to launch success. High-profile setbacks tied to fill-finish and device-component manufacturing, particularly for prefilled syringes, autoinjectors and combination products, have made supply chain capability a launch-critical hire. We consistently see launches delayed not by clinical or regulatory issues but by manufacturing-component readiness. For advanced therapies, where viral-vector and cell-processing capacity is genuinely scarce, the problem is sharper still.

What to do now. Hire CMC lifecycle managers and supply chain readiness leaders into the launch team, not into operations. They should be reporting into the launch governance structure at least twelve months before approval and contributing to the launch readiness review. Where the asset depends on a specific contract manufacturer or fill-finish partner, hire a dedicated external operations lead with direct CDMO management experience. For ATMP assets, prioritise candidates with viral-vector or cell-therapy manufacturing exposure. The talent pool is shallow, and the people who have worked through a recent commercial scale-up are the ones who prevent the next one from slipping.

The risk if you don't. The launch goes ahead clinically and falls over operationally. The companies that built supply chain capability into the launch hiring brief are the ones with full shelves at month one. The companies that did not are explaining to the board why an approved asset is supply-constrained.

Salary benchmarks for European commercialisation and launch roles in 2026 reflect the pressure of the JCA window, the GLP-1-driven therapeutic concentration, and the patent-cliff M&A activity outlined above. The figures below are total base salary ranges drawn from live recruitment processes and recent offers across the UK and Ireland, the DACH region, and France and Benelux. They do not include long-term incentive equivalents, which can add 15–30% at senior levels. Headline ranges alone don't tell the story. Therapeutic specialism (oncology, rare disease, ATMP, GLP-1) consistently commands a premium of 8–15% over the broader range, and candidates who have run a successful JCA-era launch are now commanding the top of the band almost as a rule.

Indicative European base salary ranges, 2026. Equity and long-term incentives not included. Premiums of 8–15% are typical for oncology, rare disease and ATMP specialisms.

Three patterns stand out. First, DACH compensation is broadly the highest across most senior commercial and launch roles, reflecting both the cost of living in Germany and Switzerland and the depth of regional pharma headquarters demand. Second, MSL compensation has tightened across geographies as the role has matured from a generalist field function into a digitally fluent strategic one. Third, supply chain and CMC roles have moved closer to commercial pay parity than they were even two years ago. The launches that have stumbled on manufacturing readiness have done the recruiting argument no harm.

Pharmaceutical R&D returns in 2026 are stronger than they have been in over a decade, but unevenly so. The gains depend on a narrow set of high-value assets, and the gap between the headline IRR and the GLP-1-stripped IRR is widening, not narrowing. For hiring leaders, the practical implication is direct. ROI metrics are not a finance department abstraction; they are a real-time signal of where scientific, medical and commercial talent should be flowing.

The companies that align their hiring strategy to their portfolio strategy, which recognise launch readiness is built twelve to twenty-four months ahead of approval, not after, and that the EU JCA window has compressed the timeline by months rather than weeks, are the ones converting strong assets into strong launches. The companies that treat commercialisation hiring as a post-approval activity will continue to discover that even excellent science can stall in the gap between regulatory success and commercial readiness.